cessation ccl2 inhibition accelerates breast cancer metastasis promoting angiogenesis 
secretion c-c chemokine ligand ccl2 mammary tumours recruits ccr2-expressing inflammatory monocytes primary tumours metastatic sites ccl2 neutralization mice inhibits metastasis retaining monocytes bone marrow report paradoxical effect ccl2 four syngeneic mouse models metastatic breast cancer surprisingly interruption ccl2 inhibition leads overshoot metastases accelerates death result monocyte release bone marrow enhancement cancer cell mobilization primary tumour well blood vessel formation increased proliferation metastatic cells lungs interleukin il- vascular endothelial growth factor vegf-a-dependent manner notably inhibition ccl2 il markedly reduced metastases increased survival animals ccl2 implicated various neoplasias adopted therapeutic target- however results call caution considering anti-ccl2 agents monotherapy metastatic disease highlight tumour microenvironment critical determinant successful anti-metastatic therapy 
